Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Key facts

Sponsor

Radiation Therapy Oncology Group

Principal Investigator

David Raben, MD

University of Colorado, Denver

Intervention

cisplatin(drug)

Enrollment

34 enrolled

Eligibility

18 years · All sexes

Timeline

2008 – 2011

Study locations (30)

• Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
• Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States
• CCOP - Christiana Care Health Services, Newark, Delaware, United States
• Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
• Winship Cancer Institute of Emory University, Altanta, Georgia, United States
• Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States
• Cancer Institute at St. John's Hospital, Springfield, Illinois, United States
• Saint John's Cancer Center at Saint John's Medical Center, Anderson, Indiana, United States
• Methodist Cancer Center at Methodist Hospital, Indianapolis, Indiana, United States
• Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States
• James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States
• Charach Cancer Center at Huron Valley - Sinai Hospital, Commerce, Michigan, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of head and neck

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07333274
  Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
  Shandong Cancer Hospital and Institute
• RECRUITINGPHASE3NCT07026474
  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
  Universität des Saarlandes
• RECRUITINGPHASE1NCT07182149
  A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
  Normunity AccelCo, Inc.
• RECRUITINGNANCT07203911
  Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
  Tobias Todsen
• RECRUITINGNANCT07180901
  Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
  Centre hospitalier de l'Université de Montréal (CHUM)
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415
  Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
  China Medical University Hospital
• RECRUITINGPHASE2NCT07088211
  Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• RECRUITINGPHASE2NCT07040956
  A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
  West China Hospital

See all trials for Squamous cell carcinoma of head and neck →